PL1718338T3 - Kompozycje oraz sposoby do celowanego dostarczania leku in vitro oraz in vivo do ssaczych komórek poprzez bakteriopochodne nienaruszone minikomórki - Google Patents

Kompozycje oraz sposoby do celowanego dostarczania leku in vitro oraz in vivo do ssaczych komórek poprzez bakteriopochodne nienaruszone minikomórki

Info

Publication number
PL1718338T3
PL1718338T3 PL05702361T PL05702361T PL1718338T3 PL 1718338 T3 PL1718338 T3 PL 1718338T3 PL 05702361 T PL05702361 T PL 05702361T PL 05702361 T PL05702361 T PL 05702361T PL 1718338 T3 PL1718338 T3 PL 1718338T3
Authority
PL
Poland
Prior art keywords
vitro
targeted
compositions
methods
drug delivery
Prior art date
Application number
PL05702361T
Other languages
English (en)
Inventor
Himanshu Brahmbhatt
Jennifer Macdiarmid
Original Assignee
Engeneic Molecular Delivery Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engeneic Molecular Delivery Pty Ltd filed Critical Engeneic Molecular Delivery Pty Ltd
Publication of PL1718338T3 publication Critical patent/PL1718338T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL05702361T 2004-02-02 2005-01-27 Kompozycje oraz sposoby do celowanego dostarczania leku in vitro oraz in vivo do ssaczych komórek poprzez bakteriopochodne nienaruszone minikomórki PL1718338T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54059004P 2004-02-02 2004-02-02
EP20050702361 EP1718338B1 (en) 2004-02-02 2005-01-27 Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
PCT/IB2005/000204 WO2005079854A1 (en) 2004-02-02 2005-01-27 Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells

Publications (1)

Publication Number Publication Date
PL1718338T3 true PL1718338T3 (pl) 2015-12-31

Family

ID=34885947

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05702361T PL1718338T3 (pl) 2004-02-02 2005-01-27 Kompozycje oraz sposoby do celowanego dostarczania leku in vitro oraz in vivo do ssaczych komórek poprzez bakteriopochodne nienaruszone minikomórki

Country Status (18)

Country Link
US (3) US9867785B2 (pl)
EP (2) EP2992901B1 (pl)
JP (2) JP5060787B2 (pl)
CN (2) CN1925873B (pl)
AU (2) AU2005215254B2 (pl)
CA (2) CA2788707C (pl)
DK (2) DK2992901T3 (pl)
ES (2) ES2544652T3 (pl)
HR (1) HRP20150828T8 (pl)
HU (1) HUE025292T2 (pl)
ME (1) ME02251B (pl)
NZ (1) NZ549139A (pl)
PL (1) PL1718338T3 (pl)
PT (1) PT1718338E (pl)
RS (1) RS54149B1 (pl)
SG (3) SG135175A1 (pl)
SI (1) SI1718338T1 (pl)
WO (1) WO2005079854A1 (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004249172A1 (en) 2003-06-24 2004-12-29 Baxter International Inc. Specific delivery of drugs to the brain
US8986736B2 (en) 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
DK2992901T3 (da) 2004-02-02 2020-01-27 Engeneic Molecular Delivery Pty Ltd Sammensætninger og fremgangsmåder til målrettet in vitro- og in vivo-medicinlevering til pattedyrceller via bakterielt afledte intakte miniceller
RU2006144851A (ru) 2004-06-15 2008-06-20 Бакстер Интернэшнл Инк. (Us) Применение терапевтических средств ex-vivo в виде твердых микрочастиц
HUE024999T2 (en) 2004-08-26 2016-02-29 Engeneic Molecular Delivery Pty Ltd Introducing functional nucleic acids into mammalian cells with bacterial intact minicells
HRP20150328T1 (hr) 2007-03-30 2015-05-22 Engeneic Molecular Delivery Pty Ltd. Bakterijski dobivene, intaktne mini-stanice koje obuhvaä†aju funkcionalnu nukleinsku kiselinu, bez plazmida, za in vivo dopremu do stanica sisavaca
JP2010540466A (ja) 2007-09-24 2010-12-24 ザ ユニバーシティ オブ クイーンズランド 分子送達ベシクル
KR20200075044A (ko) 2008-01-22 2020-06-25 아라임 파마슈티칼즈, 인크. 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
RU2496482C2 (ru) 2008-03-05 2013-10-27 Бакстер Интернэшнл Инк. Композиции и способы для доставки лекарственных средств
US20100112670A1 (en) 2008-06-25 2010-05-06 Vaxiion Therapeutics, Inc. Regulated genetic suicide mechanism compositions and methods
US10952965B2 (en) 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
CN102596177B (zh) 2009-07-01 2014-05-28 阿昂梅迪克斯公司 来源于有核哺乳动物细胞的微囊泡及其应用
IT1401457B1 (it) * 2010-06-11 2013-07-26 Fond I R C C S Istituto Neurologico Carlo Besta Carrier di tipo cellulare per il trasporto mirato di almeno una molecola e/o almeno un composto molecolare ad almeno una cellula bersaglio in un mammifero umano o non umano
BR112013000024B1 (pt) 2010-07-01 2021-11-23 Aeon Medix Inc Composição para entregar um agente anticancer e método para preparação de microvesículas carregadas com um agente anticâncer, a partir de protoplastos de células bacterianas
CA2827443C (en) 2011-02-15 2021-07-06 Vaxiion Therapeutics, Inc. Therapeutic compositions and methods for antibody and fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells
RU2664698C2 (ru) * 2011-12-13 2018-08-21 Энджинеик Молекьюлар Деливери Пти Лтд Полученные из бактерий интактные мини-клетки для доставки лекарственных средств к опухолям мозга
AU2013327059B2 (en) 2012-10-02 2018-11-08 Vaxiion Therapeutics, Llc Immunomodulatory minicells and methods of use
US9733222B2 (en) * 2012-10-03 2017-08-15 Waters Technologies Corporation Rapid analysis of steroids and steroid derivatives
JP2016507543A (ja) * 2013-02-07 2016-03-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 小胞を含む医薬組成物
EP3009149B1 (en) * 2013-06-11 2021-10-20 House Wellness Foods Corporation Carrier for transporting substance to macrophages
AP2016009153A0 (en) * 2013-10-04 2016-04-30 Engeneic Molecular Delivery Pty Ltd Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma
AU2015326407C1 (en) * 2014-10-03 2021-06-24 Engeneic Molecular Delivery Pty Ltd Enhanced loading of intact, bacterially derived vesicles with small molecule compounds
CN104388459B (zh) * 2014-10-29 2017-03-08 四川农业大学 使细菌自主产微细胞的方法及一株自产微细胞细菌突变株
KR101708424B1 (ko) * 2015-03-04 2017-02-20 전남대학교산학협력단 코리네박테리움 속 박테리아 및 이로부터 유래된 미니셀 그리고 이의 용도
CN108348624B (zh) 2015-08-04 2021-07-27 瓦克星治疗有限责任公司 基于细菌小细胞的生物药物的电离辐射灭菌以及使用方法
KR101858840B1 (ko) 2016-01-15 2018-05-16 단국대학교 천안캠퍼스 산학협력단 집먼지진드기 유래 알레르겐에 의한 과민반응 면역조절제
WO2017192863A1 (en) 2016-05-04 2017-11-09 L.E.A.F. Holdings Group Llc Targeted liposomal gemcitabine compositions and methods thereof
CA3039010A1 (en) 2016-10-06 2018-04-12 Engeneic Molecular Delivery Pty Ltd Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same
US11642362B2 (en) 2017-07-06 2023-05-09 National University Of Singapore Methods of inhibiting cell proliferation and METTL8 activity
WO2019204154A1 (en) 2018-04-18 2019-10-24 Reyoung Corporation Compositions and methods for treating liver cancer
WO2019217164A1 (en) 2018-05-09 2019-11-14 Reyoung Corporation Compositions and methods for treating cancer and other diseases
EP3826654A4 (en) 2018-07-23 2022-07-06 EnGeneIC Molecular Delivery Pty Ltd COMPOSITIONS COMPRISING MINICELLS OF BACTERIAL ORIGIN AND THEIR METHODS OF USE
US20220031862A1 (en) * 2018-12-10 2022-02-03 Flagship Pioneering Innovations Vi, Llc Achromosomal dynamic active systems
AU2020205040A1 (en) 2019-01-04 2021-08-12 Engeneic Molecular Delivery Pty Ltd Encapsulated glycolipid antigens for treatment of neoplastic diseases
EP3952645A4 (en) * 2019-04-08 2023-08-23 University Of Massachusetts Localization of payload delivery systems to tumor sites via beacon cell targeting
US20220202950A1 (en) * 2019-05-01 2022-06-30 Engeneic Molecular Delivery Pty Ltd Compositions comprising bacterially derived intact minicells for theranostic applications
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
CN114053430A (zh) * 2020-07-29 2022-02-18 深圳先进技术研究院 一种负载纳米载药颗粒的细菌及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4496778A (en) 1983-10-03 1985-01-29 Exxon Research & Engineering Co. Process for the hydroxylation of olefins using molecular oxygen, an osmium containing catalyst, a copper Co-catalyst, and an aromatic amine based promoter
CA1270198C (en) 1984-08-08 1990-06-12 Marcel B Bally ENCAPSULATION OF ANTINEOPLASTIC AGENTS IN LIPOSONES
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) * 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
WO1996032930A1 (en) 1995-04-18 1996-10-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposome drug-loading method and composition
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
KR20070118315A (ko) 1999-04-21 2007-12-14 와이어쓰 폴리뉴클레오티드 서열의 기능을 억제하기 위한 조성물
WO2002016590A2 (en) 2000-08-21 2002-02-28 Clonex Development, Inc. Methods and compositions for increasing protein yield from a cell culture
EP1372721A4 (en) 2001-03-07 2008-04-02 Childrens Medical Center METHOD FOR SCREENING PEPTIDE DISPLAY LIBRARIES WITH A MINIMUM DISPLAY
US7011946B2 (en) 2001-05-22 2006-03-14 Trustees Of Tufts College In vivo assay for identification of antimicrobial agents
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
US20030166099A1 (en) * 2001-06-05 2003-09-04 Sabbadini Roger A. Minicells comprising membrane proteins
JP4458846B2 (ja) * 2001-10-15 2010-04-28 エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド ｉｎｖｉｔｒｏおよびｉｎｖｉｖｏにおけるＤＮＡ導入および遺伝子療法のためのベクターとしての完全なミニ細胞
AU2002318168B2 (en) * 2002-02-25 2007-12-13 Vaxiion Therapeutics, Llc Minicell compositions and methods
US20030207833A1 (en) 2002-02-25 2003-11-06 Neil Berkley Pharmaceutical compositions with minicells
US20030203481A1 (en) * 2002-02-25 2003-10-30 Surber Mark W. Conjugated minicells
US7611885B2 (en) 2003-06-24 2009-11-03 Engeneic Molecular Delivery Pty, Ltd. Pharmaceutically compatible method for purifying intact bacterial minicells
DK1694361T3 (da) 2003-12-09 2011-06-06 Engeneic Molecular Delivery Pty Ltd Målrettet levering til ikke-phagocytiske pattedyrceller via bakterielt afledte intakte miniceller
DK2992901T3 (da) * 2004-02-02 2020-01-27 Engeneic Molecular Delivery Pty Ltd Sammensætninger og fremgangsmåder til målrettet in vitro- og in vivo-medicinlevering til pattedyrceller via bakterielt afledte intakte miniceller
HUE024999T2 (en) 2004-08-26 2016-02-29 Engeneic Molecular Delivery Pty Ltd Introducing functional nucleic acids into mammalian cells with bacterial intact minicells
US20090123426A1 (en) 2004-12-17 2009-05-14 Chiang Li Compositions for Bacterial Mediated Gene Silencing and Methods of Using the Same
US9878043B2 (en) 2006-06-23 2018-01-30 Engeneic Molecular Delivery Pty Ltd Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells

Also Published As

Publication number Publication date
SG169373A1 (en) 2011-03-30
HK1155665A1 (en) 2012-05-25
CN1925873A (zh) 2007-03-07
SG135174A1 (en) 2007-09-28
CN102028953B (zh) 2013-10-30
AU2005215254A1 (en) 2005-09-01
EP1718338B1 (en) 2015-05-06
US20180280311A1 (en) 2018-10-04
JP5571031B2 (ja) 2014-08-13
JP5060787B2 (ja) 2012-10-31
CA2788707C (en) 2014-02-25
EP1718338A1 (en) 2006-11-08
CN102028953A (zh) 2011-04-27
CA2556248C (en) 2013-04-02
US9867785B2 (en) 2018-01-16
ES2544652T3 (es) 2015-09-02
EP2992901B1 (en) 2019-10-23
NZ549139A (en) 2009-11-27
RS54149B1 (sr) 2015-12-31
SI1718338T1 (sl) 2015-09-30
WO2005079854A1 (en) 2005-09-01
AU2005215254B2 (en) 2009-11-12
AU2010200599B2 (en) 2011-09-22
HUE025292T2 (en) 2016-02-29
JP2011178798A (ja) 2011-09-15
US20140220116A1 (en) 2014-08-07
PT1718338E (pt) 2015-09-21
EP1718338A4 (en) 2009-07-22
US10799461B2 (en) 2020-10-13
HRP20150828T8 (hr) 2016-04-22
EP2992901A1 (en) 2016-03-09
CA2788707A1 (en) 2005-09-01
CA2556248A1 (en) 2005-09-01
AU2010200599A1 (en) 2010-03-11
ME02251B (me) 2015-12-31
JP2007534667A (ja) 2007-11-29
SG135175A1 (en) 2007-09-28
DK2992901T3 (da) 2020-01-27
ES2765426T3 (es) 2020-06-09
DK1718338T3 (en) 2015-08-10
CN1925873B (zh) 2011-02-09
HRP20150828T1 (xx) 2015-09-11
US20180133163A1 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
PT1718338E (pt) Composições e métodos de libertação direcionada de fármacos in vitro e in vivo por meio de minicélulas intactas derivadas de bactérias
EP1594883A4 (en) COVALENT MODIFICATION OF RNA FOR DISTRIBUTION IN VITRO / I AND IN VIVO / I
EP1791959A4 (en) DISPOSAL OF FUNCTIONAL NUCLEIC ACIDS ON MAMMALIAN CELLS OVER BACTERIA ORIGINAL INTACT MINIMIZERS
PL2089511T3 (pl) Rozrost in vitro komórek pochodzących z tkanki pępowinowej wykorzystujących mikronośniki
EP2049130A4 (en) SOFT TISSUE LOAD COMPOSITION COMPRISING AUTOLOGOUS CELL CULTURE PRODUCT DERIVED FROM DERMA AND HYALURONIC ACID
EP1636385A4 (en) INHIBITION OF GENE FUNCTION BY IN VIVO DISTRIBUTION OF GENE EXPRESSION INHIBITORS BASED ON POLYNUCLEOTIDES IN MAMMALIAN CELLS
IL243462A (en) Oligomers and phosphate-based conjugates for insertion of drugs into living cells and cell nuclei
WO2010062911A3 (en) Compositions and methods of functionally enhanced in vitro cell culture system
IL164079A0 (en) Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
EP1585560A4 (en) ADMINISTRATION OF MOLECULES AND COMPLEXES TO IN VIVO MAMMAL CELLS
WO2007147014A8 (en) Method and systems for using biopolymer-based beads and hydrogels
IL186535A0 (en) Pharmaceutical compositions for elimination of heterogeneous and mixed cell populations in tumors
WO2011082038A3 (en) Improved reprogramming compositions
IL202184A (en) A method for enhancing the expression of exogenous T cell sequences, a method based kit, a pharmacological preparation containing at least one stimulatory substance and an adeno viral vector containing the exogenous sequence
IL266122A (en) Stable serum-free cell-to-cell gene transfer and production of recombinant human proteins in human cell lines
EP2155235A4 (en) OXYGENIC COMPOSITIONS FOR IMPROVING THE SURVIVAL OF CELLS AND TISSUE IN VIVO
ZA200509760B (en) Composition for maintaining organ and cell viability
EP2506857A4 (en) ISSUE OF MRNA FOR THE PROTEIN AND ENZYME REPRODUCTION OF HUMAN-ENVIRONMENTAL DISEASES
WO2003099225A3 (en) Compositions for delivering nucleic acids to cells
EP4495237A3 (en) Novel lipids and compositions for the delivery of therapeutics
MX357691B (es) Il-15 y il-15r-alfa mejoradas para expresion en celulas mamiferas.
MX2012000455A (es) Composiciones de matriz extra-celular y medio acondicionado a partir de celulas cultivadas bajo condiciones hipoxicas.
FR2931163B1 (fr) Lignee de cellules dendritiques plasmacytoides utilisee en therapie cellulaire active ou adoptive
WO2006045116A3 (en) In vivo site-specific incorporation of n-acetyl-galactosamine amino acids in eubacteria
EP2488210A4 (en) METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION USING IN VITO OR IN VITRO-ADMINISTERED OLIGONUCLEOTIDE MEDICAMENTS